IDEXX LABORATORIES INC /DE — Director's Dealing 2016

Nov 30, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2016-11-28

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-11-28	Common Stock	M	13188	$38.7950	Acquired	1001043	Direct
2016-11-28	Common Stock	S	13188	$119.5677	Disposed	987855	Direct
2016-11-28	Common Stock	M	2576	$38.7950	Acquired	990431	Direct
2016-11-29	Common Stock	M	14236	$38.7950	Acquired	1004667	Direct
2016-11-29	Common Stock	S	14236	$119.9662	Disposed	990431	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-11-28	Non-Qualified Stock Option (right-to-buy)	$38.7950	M	13188	Disposed	2018-02-13	Common Stock (13188)	Direct
2016-11-28	Incentive Stock Option (right-to-buy)	$38.7950	M	2576	Disposed	2018-02-13	Common Stock (2576)	Direct
2016-11-29	Non-Qualified Stock Option (right-to-buy)	$38.7950	M	14236	Disposed	2018-02-13	Common Stock (14236)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	98000	Indirect

Footnotes

F1: Represents the weighted average sales price of the shares sold ranging from a low of $119.40 to a high of $119.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $119.82 to a high of $120.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F4: Grant of option to buy 1,288 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F5: Not applicable.